Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine ... response to at least two oral antidepressants,” the pharmaceutical giant said Tuesday. An estimated 21 million ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson JNJ4.13%increase ... red down pointing triangle for about $15 billion, evidence of the pharmaceutical industry’s renewed interest in neuroscience bets with vast but unrealized ...

Johnson & Johnson is a holding company ... It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15.

nor has Johnson & Johnson's stock market performance. Is the pharmaceutical giant still worth investing in? Some might describe Johnson & Johnson's business as boring, but sometimes, that's not ...